Convenience

Recent Product Updates New, enhanced Prescribing Information (PI) is available for Humate-P®, and includes: Clinical data on use of Humate-P® in surgical patients Expanded information on dosing New virus reduction capacity. View the new Prescribing Information now. Humate-P® is available with: Smaller diluent Mix2VialTM needleless transfer device 50% less diluent in all assay sizes This means: Less infusion time Smaller vials and packaging Less storage space Mix2Vial™ is a simple way to reconstitute Humate-P® offering: Needle-free transfer device Less risk of accidental injury Less time spent preparing product Simple process encourages independence Built-in filter For use with all Luer-Lok® syringes For more information on Mix2Vial™, call Consumer Affairs at 1-888-508-6978 View a virtual step-by-step demonstration of how Mix2Vial works, please click here. You can save time by self-infusing with Humate-P at home using Mix2Vial. Watch a video on the 6 steps of self-infusion. Reminder: When stored at refrigerator temperature, 2-8°C (36-46°F), Humate-P® is stable for the period indicated by the expiration date on its label. Within this period, Humate-P® may be stored at room temperature not to exceed 30°C (86°F), for up to six months.

Luer-Lok^® is a trademark of Becton, Dickinson and Company.

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.